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Abstract 
Introduction: Encephalopathy and convulsive seizures are rare manifestations of metronida-
zole toxicity. The incidence is unknown, but the condition has most frequently been reported 
in patients in their fifth to sixth decades. Usually, this condition is regarded as reversible, but 
permanent deficits and even death have been reported. Case Report: A 66-year-old female 
patient undergoing metronidazole treatment for pleural empyema was admitted to our insti-
tution after her second episode of seizure. Over the course of 1 week after admittance, the 
patient developed several convulsive seizures along with progressive cerebellar dysfunction 
and cognitive impairment. MRI revealed bilateral, symmetrical hyperintense signal changes in 
the pons and dentate nuclei. EEG, ECG, lumbar puncture, and blood samples were normal. 
The patient improved already 2–3 days after discontinuation of metronidazole and was dis-
charged fully recovered after 17 days. Follow-up clinical assessment and MRI were unre-
markable. Conclusion: Metronidazole-induced encephalopathy is a rare condition, and due 
to a general lack of awareness the diagnosis is often delayed. This condition should be con-
sidered in metronidazole-treated patients presenting with unprovoked seizures, myoclonus, 
cerebellar signs, and encephalopathy. Characteristic MRI lesions may support the clinical 
suspicion. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Metronidazole, a 5-nitroimidazole, is one of the most commonly used antibiotics against 
anaerobic bacterial and amoebic infections worldwide. It is generally well tolerated but may 
in rare cases cause neurological side effects. Metronidazole-induced encephalopathy is a 
challenging side effect, which is probably underdiagnosed [1], most likely due to general 
unawareness of this condition. The incidence is not known but reviews of case reports con-
cerning metronidazole-induced encephalopathy suggest a peak incidence in patients be-
tween 50 and 60 years old [2]. In most cases, it is a reversible condition, but permanent se-
quelae and death have been reported [2, 3]. In this paper, we present a case of metronida-
zole-induced encephalopathy with generalized and focal seizures in a previously nonepilep-
tic patient. 
Case Report 
A 66-year-old female with a medical history of previous smoking and chronic depres-
sion had recently been prescribed 6 weeks of oral metronidazole 500 mg three times daily 
along with amoxicillin and clavulanic acid for pleural empyema. After 34 days of treatment, 
she noticed paresthesia of toes and fingertips. On day 36 of treatment, she had a seizure with 
loss of consciousness, facial contractions, shivering of the arms, and prolonged awakening. 
She was brought to an emergency department where physical examination, ECG, and brain 
CT were normal, and was discharged without neurological consultation. The following days, 
she felt unwell and on the day 45 of metronidazole treatment, a second seizure occurred, 
after which she was admitted to our Department. The husband had witnessed a few minutes 
of unconsciousness accompanied by contractions of the upper extremities and biting of the 
tongue followed by prolonged reawakening. Both seizures had been preceded by nausea and 
a tightening epigastric sensation. Neurological examination revealed decreased sensation of 
touch distally on upper and lower extremities but was otherwise unremarkable. Point-of-
care arterial lactate upon admission was elevated (6.3 mmol/L). EEG, ECG, and blood sam-
ples, including kidney and liver function, hemoglobin and coagulation factors were all nor-
mal, except marginally elevated leukocytes and platelets (respectively 11.5 × 109 cells/L and 
484 × 109 cells/L). Brain MRI with gadolinium contrast was performed the day after admis-
sion and showed only slight cortical atrophy; however, interpretation was impaired by poor 
image quality due to movement artefacts. Over the following 5 days, the patient further de-
veloped multifocal myoclonus, cognitive impairment as well as truncal and limb ataxia. 
Moreover, she had several focal seizures in her face and arms. On day 7 after admission, clin-
ical suspicion of metronidazole-induced encephalopathy arose, and metronidazole was dis-
continued. Lumbar puncture showed normal protein, glucose, and cell counts. Brain MRI 
with gadolinium contrast was repeated on day 8 after admission, and metronidazole en-
cephalopathy was confirmed as the fluid-attenuated inversion recovery sequence showed 
characteristic symmetrical hyperintense signal changes in the pons and dentate nuclei (Fig. 
1a). The patient reported improvement 3 days after discontinuation of metronidazole. The 
patient was discharged 17 days after admission. At this time, she had completely recovered 
except decreased sensation of the feet. The sensory disturbances were ascribed to metroni-
dazole-induced polyneuropathy, and the patient was referred to nerve conduction studies. 
Follow-up brain MRI 6 months later showed complete remission of the hyperintense signal 
changes in the pons and dentate nuclei (Fig. 1b). 
 Case Rep Neurol 2018;10:34–37 
DOI: 10.1159/000485915 © 2018 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crn 
Sørensen et al.: Convulsive Seizures as Presenting Symptom of Metronidazole-Induced 
Encephalopathy: A Case Report 
 
 
 
 
36 
Discussion 
Metronidazole readily crosses the blood-brain barrier [4, 5], but the pathophysiological 
mechanisms behind its neurotoxicity have not yet been fully elucidated. Several mechanisms 
have been proposed. In vitro, metronidazole forms byproducts which may competitively 
inhibit thiamine [6] and can also react with catecholamines to produce neurotoxic free radi-
cals [7]. Experimental studies have suggested that metronidazole can influence levels of 
brain mono-amines [8] and bind to neuronal RNA in rats [9]. Moreover, modulation of GABA 
receptors has been suggested in canine studies [10]. 
Clinical signs of encephalopathy or the combination of reduced consciousness and ataxia 
in a patient undergoing metronidazole treatment may bring metronidazole-induced enceph-
alopathy into diagnostic considerations very early. Moreover, metronidazole-induced en-
cephalopathy may be suspected in a previously nonepileptic patient with no biochemical, 
electrophysiological, or neuroimaging evidence or risk factors of epilepsy who presents with 
new onset of multifocal myoclonus or epileptic seizures. Our patient presented with seizures 
as well as mild cognitive symptoms masked by a postictal state. Side effects of metronidazole 
were suspected from the evolving clinical picture of encephalopathy, seizures, myoclonus, 
and cerebellar disturbances.  
Diagnosis was confirmed when other possible underlying conditions were excluded and 
brain MRI displayed symmetrical lesions of the dentate nuclei and posterior pons. Ahmed et 
al. [11] first demonstrated neuroimaging findings in metronidazole-induced encephalopathy. 
Since then, several cases have been reported [2, 3]. Bilateral changes of the dentate nuclei, 
subcortical white matter, corpus callosum, and posterior pons are characteristic [2], but the 
initial MRI may be negative [12] as in the case of our patient. 
In our patient, the diagnosis of metronidazole-induced encephalopathy was established 
2–3 weeks after the first symptoms, and her condition significantly improved 2–3 days after 
cessation of metronidazole treatment. Irreversible deficits and even death have been report-
ed in the literature [13]; however, in most patients, both clinical and MRI abnormalities  
are reversible, underlining the importance of recognizing the condition as swiftly as pos-
sible [2, 3]. 
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Fig. 1. Coronal fluid-attenuated inversion recovery with gadolinium contrast recorded by a 3T MRI scanner 
during (a) and 6 months after (b) full recovery from metronidazole-induced encephalopathy. The white 
arrows mark the hyperintense signal changes in the bilateral dentate nuclei. 
 
